Evidence map›Paper›PMID 26234488›Full record

ArticleActa biomaterialia2015

Surface-mediated delivery of siRNA from fibrin hydrogels for knockdown of the BMP-2 binding antagonist noggin.

Christine J Kowalczewski, Justin M Saul

Abstract read
In one paragraph

Article in Acta biomaterialia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Enhanced Osteogenic Potential ofACS biomaterials science & engineering · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Nucleic Acid Delivery from Granular Hydrogels.Advanced healthcare materials · 2022
    Article
  10. Review
  11. Review
  12. Emerging local delivery strategies to enhance bone regeneration.Biomedical materials (Bristol, England) · 2020
    Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Christine J KowalczewskiSchool of Biomedical Engineering and Sciences, Virginia Tech-Wake Forest University, Medical Center Blvd, Winston-Salem, NC 27157, United States; Department of Chemical, Paper and Biomedical Engineering, Miami University, 650 High St, Oxford, OH 45056, United States.
Justin M SaulDepartment of Chemical, Paper and Biomedical Engineering, Miami University, 650 High St, Oxford, OH 45056, United States. Electronic address: sauljm@miamioh.edu.
Miami University · USVirginia Tech - Wake Forest University School of Biomedical Engineering & Sciences · US

Funding

Keratin hydrogel matrix for tunable growth factor delivery in bone regenerationR01AR061391 · NIAMS · MIAMI UNIVERSITY OXFORD · PI SAUL, JUSTIN · 2012 to 2015
$1.4M
NIAMS NIH HHS R01 AR061391NIAMS NIH HHS R01AR061391
6 · The paper itself

Abstract

Antagonists and inhibitory molecules responsible for maintaining tissue homeostasis can present a significant barrier to healing when tissue engineering/regenerative medicine strategies are employed. One example of this situation is the up-regulation of antagonists such as noggin in response to increasing concentrations of bone morphogenetic protein-2 (BMP-2) present from endogenous bone repair processes or delivered exogenously from biomaterials (synthetic bone grafts). While recombinant human (rh)BMP-2 delivered from synthetic bone grafts has been shown to be an effective alternative to autografts and allografts, the supraphysiological doses of rhBMP-2 have led to clinically-adverse side effects. The high rhBMP-2 dosage may be required, in part, to overcome the presence of antagonists such as noggin. Small interfering RNA (siRNA) is an appealing approach to overcome this problem because it can knock-down antagonists or inhibitory molecules in a temporary manner. Here, we conducted fundamental studies on the delivery of siRNA from material surfaces as a means to knock-down antagonists like noggin. Non-viral cationic lipid (Lipofectamine)-siRNA complexes were delivered from a fibrin hydrogel surface to MC3T3-E1 preosteoblasts that were treated with a supraphysiological dose of rhBMP-2 to achieve noggin mRNA expression levels higher than cells naïve to rhBMP-2. Confocal microscopy and flow cytometry showed intracellular uptake of siRNA in over 98% of MC3T3-E1 cells after 48 h. Doses of 0.5 and 1 μg noggin siRNA were able to significantly reduce noggin mRNA to levels equivalent to those in MC3T3-E1 cells not exposed to rhBMP-2 with no effects on cell viability. STATEMENT OF SIGNIFICANCE: Small interfering RNA (siRNA) has been considered for treatment of diseases ranging from Alzheimer's to cancer. However, the ability to use siRNA in conjunction with biomaterials to direct tissue regeneration processes has received relatively little attention. Using the bone morphogenetic protein 2 antagonist, noggin, as a model, this research describes an approach to knock-down molecules that are inhibitory to desired regenerative pathways at the mRNA level via siRNA delivery from a hydrogel surface. Interactions between the material (fibrin) surface and polycation-siRNA complexes, release of the siRNA from the material surface, high levels of cellular uptake/internalization of siRNA, and significant knockdown of the targeting (noggin) mRNA are demonstrated. Broader future applications include those to nerve regeneration, cardiovascular tissue engineering, directing (stem) cell behavior, and mitigating inflammatory responses to materials.

Indexed as

Gene Knockdown TechniquesAdsorptionAnimalsBone Morphogenetic Protein 2Carrier ProteinsCattleCell LineCell SurvivalFibrinFlow CytometryHumansHydrogelsKineticsMiceMicroscopy, ConfocalNoggin ProteinBone Morphogenetic Protein 2Carrier ProteinsFibrinHydrogelsNoggin Proteinrecombinant human bone morphogenetic protein-2Recombinant ProteinsRNA, MessengerRNA, Small InterferingTransforming Growth Factor betamRNANatural polymerRegenerative medicineTissue engineeringTransfection

Identifiers

PMID26234488
PMCPMC4562886
OpenAlexW1009208282

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.